Stock listing
NASDAQ:ADIL Adial Pharmaceuticals, Inc Stock
Home listing (NASDAQ) of Adial Pharmaceuticals, Inc
Follow Adial Pharmaceuticals, Inc into a list and get an email when it puts out news.
Share price · NASDAQ:ADIL
$4.05 USD -0.10 (-2.4%)
Close on Nov 4, 2026
- Day range
- $3.95 – $4.30 USDNov 4, 2026
- Volume
- 7,035 sharesNov 4, 2026
- Market cap
- $10.63M USDAt the close on Nov 4, 2026 · price × 2.63M shares outstanding
- Traded on an average day
- $270,267 USDMedian day 48,050 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ADIL · Home | $4.05 USD | -0.10 (-2.4%) | 7,035 | $3.95 | $4.30 | $3.945 | $4.15 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:ADIL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.05 | -0.10 | -2.4% | $3.95 | $4.30 | $3.945 | 7,035 | |
| $4.15 | +0.26 | +6.7% | $4.07 | $4.39 | $3.68 | 33,132 | |
| $3.89 | +0.08 | +2.1% | $4.70 | $4.83 | $3.802 | 43,497 | |
| $3.81 | -1.07 | -21.9% | $4.71 | $4.94 | $3.02 | 169,247 | |
| $4.88 | -0.17 | -3.4% | $4.50 | $4.97 | $3.67 | 146,921 | |
| $5.05 | +1.34 | +36.1% | $3.98 | $5.15 | $3.80 | 99,654 | |
| $3.71 | +0.03 | +0.8% | $3.72 | $3.98 | $3.67 | 7,357 | |
| $3.68 | -0.24 | -6.1% | $3.94 | $3.94 | $3.59 | 11,696 | |
| $3.92 | -0.30 | -7.1% | $4.15 | $4.28 | $3.92 | 47,359 | |
| $4.22 | +0.11 | +2.7% | $4.16 | $4.22 | $4.16 | 2,300 | |
| $4.11 | +0.29 | +7.6% | $3.75 | $4.41 | $3.75 | 21,500 | |
| $3.82 | +0.20 | +5.5% | $3.51 | $3.98 | $3.51 | 8,400 | |
| $3.62 | +0.13 | +3.7% | $3.54 | $3.66 | $3.46 | 12,100 | |
| $3.49 | +0.35 | +11.1% | $3.07 | $3.66 | $3.07 | 56,400 | |
| $3.14 | +0.14 | +4.7% | $3.00 | $3.30 | $3.00 | 13,900 | |
| $3.00 | -0.29 | -8.8% | $3.17 | $3.32 | $3.00 | 27,400 | |
| $3.29 | -0.21 | -6.0% | $3.52 | $3.87 | $3.20 | 75,400 | |
| $3.50 | -0.40 | -10.3% | $4.04 | $4.04 | $3.47 | 167,000 | |
| $3.90 | -0.07 | -1.8% | $4.03 | $4.06 | $3.90 | 3,000 | |
| $3.97 | -0.02 | -0.5% | $4.02 | $4.05 | $3.92 | 4,900 | |
| $3.99 | +0.01 | +0.3% | $3.91 | $4.09 | $3.91 | 4,400 | |
| $3.98 | -0.37 | -8.5% | $4.38 | $4.50 | $3.98 | 11,900 | |
| $4.35 | +0.23 | +5.6% | $4.05 | $4.43 | $3.92 | 60,000 | |
| $4.12 | -0.01 | -0.2% | $4.13 | $4.66 | $3.92 | 64,500 | |
| $4.13 | +0.12 | +3.0% | $4.12 | $4.45 | $3.86 | 13,400 | |
| $4.01 | -0.14 | -3.4% | $4.16 | $4.29 | $3.95 | 35,300 | |
| $4.15 | +0.11 | +2.7% | $4.04 | $4.30 | $3.97 | 29,300 | |
| $4.04 | -0.18 | -4.3% | $4.05 | $4.30 | $3.85 | 47,500 | |
| $4.22 | -0.22 | -5.0% | $4.40 | $4.56 | $4.12 | 33,200 | |
| $4.44 | +0.40 | +9.9% | $4.00 | $4.64 | $4.00 | 47,300 | |
| $4.04 | -0.16 | -3.8% | $4.25 | $4.25 | $3.77 | 60,900 | |
| $4.20 | -0.20 | -4.5% | $4.40 | $4.42 | $4.14 | 40,200 | |
| $4.40 | -0.46 | -9.5% | $4.82 | $4.82 | $4.23 | 43,700 | |
| $4.86 | -0.35 | -6.7% | $5.23 | $5.23 | $4.59 | 86,900 | |
| $5.21 | -0.03 | -0.6% | $5.25 | $5.38 | $5.04 | 21,600 | |
| $5.24 | +0.24 | +4.8% | $5.01 | $5.30 | $5.00 | 29,700 | |
| $5.00 | 0.00 | 0.0% | $5.02 | $5.18 | $4.80 | 29,000 | |
| $5.00 | +0.10 | +2.0% | $4.94 | $5.18 | $4.87 | 46,500 | |
| $4.90 | -1.10 | -18.3% | $6.06 | $6.11 | $4.80 | 108,500 | |
| $6.00 | +0.07 | +1.2% | $5.94 | $6.22 | $5.90 | 17,200 | |
| $5.93 | -0.72 | -10.8% | $6.64 | $6.65 | $5.87 | 48,700 | |
| $6.65 | -0.47 | -6.6% | $7.01 | $7.20 | $6.33 | 67,600 | |
| $7.12 | +0.46 | +6.9% | $6.61 | $7.20 | $6.27 | 50,100 | |
| $6.66 | +0.34 | +5.4% | $6.32 | $6.80 | $6.25 | 52,800 | |
| $6.32 | +0.37 | +6.2% | $5.92 | $6.43 | $5.80 | 53,800 | |
| $5.95 | +0.20 | +3.5% | $5.80 | $6.17 | $5.51 | 44,400 | |
| $5.75 | +0.15 | +2.7% | $5.57 | $5.98 | $5.30 | 69,900 | |
| $5.60 | -0.09 | -1.6% | $5.70 | $5.79 | $5.45 | 63,500 | |
| $5.69 | -0.25 | -4.2% | $5.96 | $5.96 | $5.45 | 53,600 | |
| $5.94 | +0.12 | +2.1% | $5.84 | $6.07 | $5.59 | 64,600 | |
| $5.82 | +0.42 | +7.8% | $5.35 | $5.90 | $5.19 | 32,100 | |
| $5.40 | -0.82 | -13.2% | $6.19 | $6.19 | $4.70 | 132,300 | |
| $6.22 | +0.32 | +5.4% | $5.95 | $6.41 | $5.74 | 81,700 | |
| $5.90 | +0.14 | +2.4% | $5.81 | $5.94 | $5.36 | 42,000 | |
| $5.76 | +0.31 | +5.7% | $5.44 | $5.80 | $5.41 | 83,800 | |
| $5.45 | +0.46 | +9.2% | $4.82 | $5.55 | $4.73 | 125,800 | |
| $4.99 | +1.01 | +25.4% | $3.84 | $5.08 | $3.84 | 146,000 | |
| $3.98 | -0.41 | -9.3% | $4.11 | $4.37 | $3.98 | 48,600 | |
| $4.39 | +0.08 | +1.9% | $4.35 | $4.64 | $4.26 | 52,000 | |
| $4.31 | 0.00 | 0.0% | $4.36 | $4.49 | $4.11 | 64,800 | |
| $4.31 | +0.10 | +2.4% | $4.16 | $4.493 | $4.01 | 20,446 | |
| $4.21 | +0.23 | +5.8% | $3.89 | $4.35 | $3.89 | 53,256 | |
| $3.98 | -0.82 | -17.1% | $4.80 | $4.87 | $3.70 | 100,600 | |
| $4.80 | +0.75 | +18.5% | $4.07 | $4.99 | $4.07 | 178,700 | |
| $4.05 | +0.25 | +6.6% | $3.75 | $4.20 | $3.75 | 116,600 | |
| $3.80 | +0.16 | +4.4% | $3.64 | $3.94 | $3.54 | 122,100 |
- Ticker
- NASDAQ:ADIL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Latest deck · October 2026
Merger or Acquisition (October 2026)
Merger or acquisition · 25 slides
Latest news
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Oct 28, 2026
Closed $4.88 (-3.4%) on Oct 29, 2026
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Oct 26, 2026
Closed $3.68 (-6.1%) on Oct 26, 2026
Amendment to Quarterly Report (Form 10-Q/A)
Oct 21, 2026
Closed $4.11 (+7.6%) on Oct 21, 2026
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Oct 16, 2026
Closed $3.49 (+11.1%) on Oct 16, 2026
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sep 30, 2026
Closed $4.13 (+3.0%) on Oct 1, 2026
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Jun 16, 2026
Closed $2.54 (-10.9%) on Jun 16, 2026
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Jun 11, 2026
Closed $2.98 (+38.0%) on Jun 11, 2026
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
May 11, 2026
Closed $1.44 (+0.7%) on May 11, 2026
Adial Pharmaceuticals, Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 143 in all · newest Oct 28, 2026 · oldest 2020
- Decks
- 26 decks · latest October 2026
Where Adial Pharmaceuticals, Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ADIL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ADIL | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 4, 2026
- Enterprise value
- −$11.41M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.52
Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc · NASDAQ:ADIL | US$10.63M | −US$11.41M | n/a | n/a | n/a | n/a | n/a | n/a | 1.52 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Medicenna Therapeutics Corp. · TSX:MDNA | US$11.26M | US$7.37M | n/a | n/a | n/a | 9.7× | n/a | 0.1× | 1.36 |
| Shaperon Inc. · KRX:378800 | US$11.12M | −US$8.17M | n/a | −33.9× | n/a | 0.8× | n/a | 0.0× | n/a |
| Miro Sciences Ltd · ASX:MSX | US$11.09M | US$8.03M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | n/a |
| Fractyl Health, Inc. · NASDAQ:GUTS | US$10.88M | −US$20.64M | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| TME Pharma N.V. · EURONEXT:ALTME | US$10.76M | US$12.80M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PharmAla Biotech Holdings, Inc. · CSE:MDMA | US$10.76M | US$10.59M | n/a | 12.0× | n/a | 7.9× | −126.9% | 0.0× | 0.38 |
| Anebulo Pharmaceuticals, Inc. · OTC:ANEB | US$10.60M | US$1.56M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | -0.01 |
| IRLAB Therapeutics AB Class A · OMXSTO:IRLAB_A | US$10.60M | US$9.62M | n/a | 1.2× | n/a | 1.1× | −67.9% | 0.3× | n/a |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| Median of the others | US$10.82M | US$5.77M | 0.1× | −16.3× | 1.1× | −97.4% | 0.0× | 0.90 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.05 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Celia Economides | Chief Financial Officer |
| David Rubenstein | Chief Scientist |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | |
| Q2 2026 | Aug 14, 2026 · After close | +25.4% |
| Q1 2026 | May 8, 2026 · After close | +0.7% |
| Q4 2025 | Mar 26, 2026 | −5.2% |
| Q3 2025 | Nov 13, 2025 · After close | |
| Q2 2025 | Aug 13, 2025 · After close | |
| Q1 2025 | May 14, 2025 · After close | |
| Q4 2024 | Mar 31, 2025 · After close | |
| Q3 2024 | Nov 13, 2024 · After close | |
| Q2 2024 | Aug 13, 2024 · After close |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 1, 2024 · After close | |
| Q4 2023 | Feb 20, 2024 · After close | |
| Q3 2023 | Nov 14, 2023 · After close | |
| Q2 2023 | Aug 21, 2023 · Before open | |
| Q1 2023 | May 12, 2023 · After close | |
| Q4 2022 | Mar 30, 2023 · After close | |
| Q3 2022 | Nov 14, 2022 · Before open | |
| Q2 2022 | Aug 15, 2022 · Before open | |
| Q1 2022 | May 16, 2022 · Before open | |
| Q4 2021 | Mar 28, 2022 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (October 2026) | Merger or acquisition | 25 slides | October 2026 |
| Merger or Acquisition (June 2026) | Merger or acquisition | 26 slides | June 2026 |
| Investor Presentation (February 2026) | Investor deck | 18 slides | February 2026 |
| Investor Presentation (January 2026) | Investor deck | 18 slides | January 2026 |
| Investor Presentation (June 2025) | Investor deck | 20 slides | June 2025 |
| Investor Presentation (January 2025) | Investor deck | 27 slides | Jan 13, 2025 |
| Investor Presentation (January 2025) | Investor deck | 20 slides | January 2025 |
| Investor Presentation (November 2024) | Investor deck | 19 slides | November 2024 |
| Investor Presentation (June 2024) | Investor deck | 22 slides | June 2024 |
| Investor Presentation (May 2024) | Investor deck | 23 slides | May 2024 |
All 26 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 23 slides | February 2024 |
| Investor Presentation (November 2023) | Investor deck | 26 slides | November 2023 |
| H.C. Wainwright Global Investment Conference 2023 | Conference | 26 slides | Sep 11, 2023 |
| Jefferies Healthcare Conference 2023 | Conference | 28 slides | Jun 9, 2023 |
| Investor Presentation (April 2023) | Investor deck | 30 slides | April 2023 |
| Investor Presentation (March 2023) | Investor deck | 9 slides | Mar 7, 2023 |
| Investor Presentation (August 2022) | Investor deck | 28 slides | August 2022 |
| Investor Presentation (May 2022) | Investor deck | 28 slides | May 2022 |
| Investor Presentation (January 2022) | Investor deck | 28 slides | January 2022 |
| Investor Presentation (April 2019) | Investor deck | 23 slides | Apr 30, 2019 |
| IPO Roadshow (February 2019) | IPO roadshow | 23 slides | Feb 13, 2019 |
| Investor Presentation (September 2018) | Investor deck | 23 slides | Sep 24, 2018 |
| IPO Roadshow (July 2018) | IPO roadshow | 30 slides | Jul 10, 2018 |
| IPO Roadshow (November 2017) | IPO roadshow | 30 slides | Nov 27, 2017 |
| IPO Roadshow (October 2017) | IPO roadshow | 29 slides | Oct 25, 2017 |
| IPO Roadshow (September 2017) | IPO roadshow | 29 slides | Sep 28, 2017 |
Financings
| Raise | Date |
|---|---|
| Private placement of prefunded warrants Update: about US$32M Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital Insiders: Insiders and management participated Use of proceeds: Fund operations into 2028, including IND-enabling studies and initiation of the Phase 1 trial of AT177 in ulcerative colitis | Oct 28, 2026 |
| Private placement of pre-funded warrants and common warrants Tranche closed: US$32M raised · US$2.7489 a share · common warrants to purchase up to 11,780,948 shares of common stock, sold with… · Lucid Capital Markets +1 Dealers: Lucid Capital Markets (lead), TD Cowen Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital (one of the lead investors) Insiders: insiders and management participated Use of proceeds: Advance its lead colon-targeted AhR program through key clinical milestones | Jun 16, 2026 |
| Warrant exercise of series C-1 and Series E warrants exercised for common stock Announced: about US$2.86M · US$0.31 a share · Warrants at US$0.31 for 24 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Buyers: existing healthcare-focused institutional investor (exercising the Existing Warrants for approximately $2.86 million) Use of proceeds: Working capital and other general corporate purposes | Nov 26, 2025 |
| Public offering of shares of common stock with Series D and Series E warrants Announced: about US$3.6M · US$0.3251 a share · Warrants at US$0.35 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Working capital and general corporate purposes | Jun 17, 2025 |
| Warrant exercise of series B and Series C Warrants exercised for common stock Announced: about US$2.75M · US$0.74 a share · Warrants at US$0.74 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Use of proceeds: Working capital and other general corporate purposes | May 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 565 | 565 | 564 | 60.5K | 55.1K | 564 | 565 | 563 | 565 | 565 |
| Gross profit | -565 | -565 | -564 | -60.5K | -55.1K | -564 | -565 | -563 | -565 | -565 |
| Research and development | 2.62M | 3.23M | 1.27M | 1.95M | 8.40M | 5.85M | 3.97M | 368.5K | 182.1K | 146.1K |
| Selling, general and administrative | 5.18M | 5.06M | 5.62M | 8.91M | 9.34M | 5.07M | 4.28M | 6.62M | 813.2K | 264.7K |
| Operating income | -7.80M | -8.28M | -6.89M | -10.9M | -19.3M | -10.9M | -8.24M | -6.99M | -995.3K | -410.8K |
| Depreciation and amortization | 565 | 565 | 564 | 564 | 55.1K | 564 | 565 | 563 | 565 | 565 |
| EBITDA | -7.80M | -8.28M | -6.89M | -10.9M | -19.2M | -10.9M | -8.24M | -6.99M | -994.7K | -410.2K |
| Interest expense | 585.2K | 3.61M | 0 | 0 | 1.17M | 144.5K | 9.64K | |||
| Income before tax | -7.98M | -13.2M | -7.00M | -10.8M | -19.5M | -10.9M | -8.59M | -11.6M | -1.14M | -420.2K |
| Income tax | -1.88M | -502 | -94.1K | -32.5K | -76.1K | -3.48M | 367 | 9.64K | ||
| Net income | -7.98M | -13.2M | -5.12M | -12.7M | -19.4M | -10.9M | -8.59M | -11.6M | -1.14M | -420.2K |
| Earnings per share, basic | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 | -54.96 |
| Earnings per share, diluted | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M | 4.40M | 6.78M | 3.87M | 18.2K | 88.0K |
| Receivables | 41.8K | 35.1K | ||||||||
| Current assets | 6.18M | 4.06M | 3.20M | 4.78M | 6.46M | 5.14M | 7.67M | 4.69M | 27.2K | 141.4K |
| Property, plant and equipment | 50.4K | 58.1K | ||||||||
| Goodwill | 249.0K | 249.0K | 0 | |||||||
| Total assets | 6.67M | 5.04M | 4.74M | 5.73M | 7.47M | 5.49M | 7.68M | 4.70M | 34.5K | 151.5K |
| Accounts payable | 655.0K | 250.1K | 103.3K | 276.4K | 286.2K | 648.7K | 190.2K | 99.7K | 342.1K | 20.0K |
| Current liabilities | 1.40M | 975.9K | 653.1K | 1.79M | 2.72M | 1.51M | 539.1K | 258.0K | 1.03M | 255.0K |
| Total debt | 207.4K | 257.0K | 689.3K | 234.3K | ||||||
| Total liabilities | 1.40M | 975.9K | 653.1K | 2.46M | 3.97M | 1.51M | 539.1K | 258.0K | 1.03M | 255.0K |
| Shareholders' equity | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M | 3.99M | 7.14M | 4.44M | -997.6K | -103.5K |
| Shares outstanding | 1.11M | 258.8K | 1.66M | 1.07M | 20.9M | 14.4M | 10.4M | 6.86M | 3.27M | 7.64K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.49M | -6.92M | -6.81M | -11.2M | -11.9M | -7.63M | -6.34M | -2.50M | -494.9K | -274.4K |
| Capital spending | -3 | 0 | -6.81M | -5 | -64.6K | -64.6K | -64.6K | -64.6K | 0 | 0 |
| Free cash flow | -6.49M | -6.92M | -6.81M | -11.2M | -12.0M | -7.63M | -6.34M | -2.50M | -494.9K | -274.4K |
| Cash from investing | 150.0K | 1.50M | -34.0K | -350.0K | -350.0K | -350.0K | 35.1K | 35.1K | ||
| Cash from financing | 8.47M | 7.85M | 4.13M | 9.13M | 13.6M | 5.61M | 9.25M | 6.35M | 390.0K | 200.0K |
| Share buybacks | -1.66K | 5.61M | 9.25M | 6.42M | 40.0K | 40.0K | ||||
| Change in cash | 2.13M | 923.4K | -1.17M | -2.06M | 1.66M | -2.38M | 2.91M | 3.85M | -69.7K | -74.4K |
Cap table
Built by 6ix from Adial Pharmaceuticals, Inc’s releases · as of Aug 12, 2026
- Common shares
- 2,625,890
- Fully diluted
- 2,625,890
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,625,890 | Aug 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Aug 12, 2026 | 2,625,890 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Vinay Shah Other companies: Azora Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 16, 2024); Virpax Pharmaceuticals, Inc. (Chief Financial Officer · Jun 20, 2023 – Jan 29, 2024 · Past); Aravive Inc (Chief Financial Officer · Oct 12, 2018 – Jan 24, 2022 · Past) | Chief Financial Officer · Since at least Nov 5, 2024 |
| Cary Claiborne Other companies: NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026); Azora Therapeutics, Inc. (Chief Executive Officer, Director · Since at least May 29, 2025) | Chief Executive Officer, Director · Since at least Apr 7, 2026 |
| Matt Davidson Other companies: Azora Therapeutics, Inc. (President and CEO, Director · Since at least Jun 11, 2026) | President and CEO, Director · Since at least Jun 11, 2026 |
| Robertson Gilliland Other companies: Azora Therapeutics, Inc. (Director · Since at least May 23, 2023) | Director · Since at least Apr 7, 2026 |
| Celia Economides | Chief Financial Officer · Since at least Oct 26, 2026 |
| David Rubenstein | Chief Scientist · Since at least Oct 16, 2026 |
Log in to ask 6ix AI your own questions about Adial Pharmaceuticals, Inc.